小分子可处理的PARP抑制剂:架构施工方法,机械学的见解和结构活动关系
Amandeep Thakur1, Mandeep Rana1, Ritika2
1School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 110031, Taiwan.
Bioorganic chemistry
|October 2, 2023
概括
药物设计策略已经推进了多ADP-ribose) 聚合酶 (PARP) 抑制剂,重振了它们在癌症治疗中的作用. 本综述详细介绍了这些策略及其对PARP抑制剂开发的影响.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 聚基聚合酶 (PARP) 在DNA修复和细胞过程中至关重要.
- PARP 抑制剂已成为有前途的癌症治疗药物.
- 为了开发新的PARP抑制剂,已经采用了各种药物设计方法.
研究的目的:
- 审查PARPs的生理功能.
- 讨论FDA批准的PARP抑制剂的药理动力学,药理动力学和相互作用概况.
- 为了全面覆盖PARP抑制剂和结构-活性关系的药物设计策略.
主要方法:
- 对PARP抑制剂药物设计策略的文献综述.
- 分析PARP抑制剂的生理功能,药理动力学和药理动力学.
- 检查结构-活动关系和生物评估数据.
主要成果:
- 通过各种设计策略,已经确定了PARP抑制剂的众多有希望的支架.
- 结构性修改显著影响酶和细胞活动.
- 生物评估为物理化学性质,ADME和药理学提供了洞察力.
结论:
- 先进的药物设计策略对开发有效的PARP抑制剂作出了重大贡献.
- PARP 抑制剂作为癌症治疗的新承诺.
- 了解结构-活性关系是优化PARP抑制剂疗效的关键.
更多相关视频
07:13Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
Published on: May 24, 2024
517
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.4K
相关概念视频
Structure-Activity Relationships and Drug Design
757
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
757
Long-patch Base Excision Repair
7.0K
Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
7.0K
